Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.…
Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer
Telomir Pharmaceuticals (NASDAQ: TELO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.3640 USD on 20 November 2026, down 73.0% over 52 weeks. Its 52-week range is 0.3530 USD to 1.580 USD: the price is 77.0% below the high and 3.1% above the low.
Its market capitalisation is 26.82M USD.
Telomir Pharmaceuticals reports return on equity of -176.1% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 4.45M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.